Relief Therapeutics Holding SA has signed a binding term sheet for a proposed business combination with MindMaze’s successor NeuroX Group SA. The envisaged combination aims to create a publicly listed, AI-based therapeutics platform integrating software-delivered, disease-modifying clinical interventions with pharmacological treatments and a comprehensive brain health platform to improve the quality of life of patients, caregivers and families..

Relief Therapeutics Holding SA 已与 MindMaze 的继任者 NeuroX Group SA 签署了一份具有约束力的条款清单，计划进行业务合并。预期的合并旨在创建一个公开上市的、基于人工智能的治疗平台，整合软件交付的疾病修饰临床干预措施、药物治疗以及全面的脑健康平台，以改善患者、护理人员和家庭的生活质量。

Based in Geneva,

总部位于日内瓦，

Relief Therapeutics

瑞利夫治疗公司

is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief’s clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions.

是一家处于商业化阶段的生物制药公司，致力于推进治疗模式并改善罕见病和衰竭性疾病患者的生活。凭借在药物递送系统和药物再利用方面的核心专长，Relief 的临床管线包括旨在满足罕见皮肤病、代谢和呼吸系统疾病中关键未满足医疗需求的创新疗法。

The Company has also successfully brought several approved products to market through licensing and distribution partnerships..

公司还通过授权和分销合作伙伴关系成功将数款获批产品推向市场。

The company has entered an agreement with NeuroX Group SA for a business combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company. NeuroX is a Swiss commercial stage company which previously acquired the assets and operations of MindMaze, a recognized leader in digital neurotherapeutics and brain health..

公司已与NeuroX集团达成业务合并协议，将创建一家规模扩大、在SIX上市、具备商业化阶段、由人工智能驱动、可扩展的健康科技公司。NeuroX是一家瑞士商业阶段公司，此前收购了数字神经治疗和脑健康领域的公认领导者MindMaze的资产和运营。

The proposed business combination aims to establish a publicly listed, AI-driven therapeutics platform that combines software-delivered, disease-modifying clinical interventions with pharmacological treatments and an all-encompassing brain health solution, with the goal of enhancing the quality of life for patients, caregivers, and families.

拟议的业务合并旨在建立一个公开上市的、由人工智能驱动的治疗平台，该平台结合了软件提供的疾病修饰临床干预、药物治疗以及全方位的脑健康解决方案，目标是提高患者、护理人员和家庭的生活质量。

NeuroX will contribute a clinically validated, risk-mitigated portfolio supported by multiple milestones achieved across technological development, regulatory approvals, and market access, as well as a solid network of pharmaceutical partners..

NeuroX将贡献一个经过临床验证、风险缓解的投资组合，该组合得到了技术开发、监管批准和市场准入等多个里程碑的支持，并且拥有一个坚实的制药合作伙伴网络。

Under the terms of the term sheet, NeuroX shareholders will exchange at closing all outstanding shares of NeuroX for newly issued shares of Relief. The transaction is based on agreed equity valuations of CHF 100 million for Relief, representing a significant premium to its current market capitalization, and CHF 1 billion for NeuroX.

根据条款说明书的条款，NeuroX 的股东将在交易结束时将其所有 NeuroX 的流通股换成新发行的 Relief 股份。该交易基于双方约定的股权估值，其中 Relief 的估值为 1 亿瑞士法郎，较其当前市值有显著溢价，而 NeuroX 的估值为 10 亿瑞士法郎。

Post-closing, Relief shareholders are expected to own approximately 9% of the combined entity on a fully diluted basis, with NeuroX shareholders holding the remaining 91%. The combined entity’s shares will continue trading on the SIX Swiss Exchange..

交易完成后，Relief股东预计将在完全稀释的基础上持有合并实体约9%的股份，NeuroX股东持有剩余的91%。合并后的实体股份将继续在瑞士证券交易所（SIX Swiss Exchange）交易。

“By entering into this transaction, we intend to bring a global pioneer in digital neurotherapeutics to the public markets through the Relief ecosystem. NeuroX, which now operates the MindMaze platform, has a compelling business model, an established track record of innovation, and a distinctive technology that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology.

“通过此次交易，我们打算通过Relief生态系统将全球数字神经治疗领域的先驱带入公开市场。NeuroX目前运营MindMaze平台，其商业模式引人注目，创新记录卓越，并拥有整合神经科学与数字治疗的独特技术，以应对神经病学中一些最紧迫的挑战。”

We believe this combination has the potential to create significant value for patients, clinicians, and shareholders. Importantly, it offers existing Relief shareholders the opportunity to participate in the growth of a scalable enterprise with potential to become a multi-billion-dollar company”, said Raghuram Selvaraju, chairman of the board of directors of Relief..

我们相信，这种组合有潜力为患者、临床医生和股东创造显著的价值。重要的是，它为现有的Relief股东提供了参与一家具有成为数十亿美元公司潜力的可扩展企业增长的机会，”Relief董事会主席拉古拉姆·塞尔瓦拉朱表示。

Transaction closing is anticipated in Q4 2025, pending standard regulatory and shareholder approvals.

预计交易将于2025年第四季度完成，但需等待标准的监管和股东批准。

(Press release)

（新闻稿）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送